Incyte Corporation (INCY) - צמיחת רווחי EPS רבעונית
Quarterly EPS dynamics demonstrate current profitability trends, where the value of -283.50 expresses the metric level. Incyte Corporation (INCY) is a biopharmaceutical leader protected by Jakafi patents and focused on high-margin hematology. Revenues are based on the commercialization of targeted therapies for autoimmune and oncological pathologies. The business is currently plateauing, diversifying its portfolio with new developments ahead of patent expirations.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_INCY_-_Incyte-Corporation_-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים Incyte Corp. (INCY): לתקופה 04.07.2022 - 14.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Incyte Corporation
Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. Positive momentum confirms the effectiveness of business scaling and the growth of the asset's fundamental value. By analyzing the growth rates of quarterly net income per share, an investor assesses the risk of overpaying for the asset. For Incyte Corporation (INCY), this indicator reflects the current dependence on Jakafi sales. Stability in this metric will prove management's ability to successfully diversify the drug portfolio.
